Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI)

Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI)

According to the data derived from several national and international registries, including SANI (Severe Asthma Network Italy), and considering the strong impact that frequent or regular use of oral corticosteroid has on quality of life (QoL) of severe asthmatics, as well as on the costs for managin...

Volledige beschrijving

Bibliografische gegevens
Hoofdauteurs:	Giorgio Walter Canonica, Francesco Blasi, Pierluigi Paggiaro, Gianenrico Senna, Giovanni Passalacqua, Antonio Spanevello, Stefano Aliberti, Diego Bagnasco, Marco Bonavia, Matteo Bonini, Luisa Brussino, Caterina Bucca, Maria F. Caiaffa, Cecilia Calabrese, Gianna Camiciottoli, Marco Caminati, Giovanna E. Carpagnano, Cristiano Caruso, Stefano Centanni, Maria E. Conte, Angelo G. Corsico, Lorenzo Cosmi, Maria T. Costantino, Nunzio Crimi, Simona D’Alò, Maria D'Amato, Stefano Del Giacco, Alessandro Farsi, Elisabetta Favero, Maria P. Foschino Barbaro, Gabriella Guarnieri, Giuseppe Guida, Manuela Latorre, Salvatore Lo Cicero, Carlo Lombardi, Luigi Macchia, Francesco Mazza, Francesco Menzella, Manlio Milanese, Marcello Montagni, Paolo Montuschi, Eleonora Nucera, Roberta Parente, Vincenzo Patella, Girolamo Pelaia, Laura Pini, Francesca Puggioni, Luisa Ricciardi, Fabio L.M. Ricciardolo, Luca Richeldi, Erminia Ridolo, Giovanni Rolla, Pierachille Santus, Nicola Scichilone, Giuseppe Spadaro, Andrea Vianello, Vittorio Viviano, Mona R. Yacoub, Maria C. Zappa, Enrico Heffler
Formaat:	Artikel
Taal:	English
Gepubliceerd in:	Elsevier 2020-10-01
Reeks:	World Allergy Organization Journal
Onderwerpen:	Severe asthma Biologics Oral corticosteroids Real-life Registr
Online toegang:	http://www.sciencedirect.com/science/article/pii/S1939455120303677

Gelijkaardige items

Patient and physician perspectives on biological treatment in severe asthma: a Severe Asthma Network Italy survey
door: Claudia Crimi, et al.
Gepubliceerd in: (2023-11-01)

Nasal polyps impact in severe asthma patients: evidences from the SANI
door: Giorgio Walter Canonica, et al.
Gepubliceerd in: (2020-08-01)

Economic impact of a more extensive use of FENO testing on the Italian population with asthma
door: Carla Rognoni, et al.
Gepubliceerd in: (2023-06-01)

Asthma severity: the patient’s point of view
door: Gabriella Guarnieri, et al.
Gepubliceerd in: (2024-12-01)

Is Bronchiectasis (BE) Properly Investigated in Patients with Severe Asthma? A Real-Life Report from Eight Italian Centers
door: Giovanna Elisiana Carpagnano, et al.
Gepubliceerd in: (2023-10-01)

Clinical-economic impact of mepolizumab in patients with severe hypereosinophilic asthma
door: Diego Bagnasco, et al.
Gepubliceerd in: (2020-08-01)

Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life
door: Diego Bagnasco, et al.
Gepubliceerd in: (2021-02-01)

Severe asthma: One disease and multiple definitions
door: Diego Bagnasco, MD, PhD, et al.
Gepubliceerd in: (2021-11-01)

Critical evaluation of asthma biomarkers in clinical practice
door: Giuseppe Guida, et al.
Gepubliceerd in: (2022-10-01)

Biologics in Severe Eosinophilic Asthma: Three-Year Follow-Up in a SANI Single Center
door: Paolo Solidoro, et al.
Gepubliceerd in: (2022-01-01)

Profiling severe asthma: Any relevance for age? An analysis from Severe Asthma Network Italy (SANI) cohort
door: Marco Caminati, MD, et al.
Gepubliceerd in: (2024-08-01)

Phenotype overlap in the natural history of asthma
door: Fabio L.M. Ricciardolo, et al.
Gepubliceerd in: (2023-05-01)

Minimal clinically important difference for asthma endpoints: an expert consensus report
door: Matteo Bonini, et al.
Gepubliceerd in: (2020-06-01)

Long-Term Efficacy of Mepolizumab at 3 Years in Patients with Severe Asthma: Comparison with Clinical Trials and Super Responders
door: Diego Bagnasco, et al.
Gepubliceerd in: (2023-08-01)

Manifesto on the overuse of SABA in the management of asthma: new approaches and new strategies
door: Giorgio Walter Canonica, et al.
Gepubliceerd in: (2021-09-01)

Biologics as well as inhaled anti-asthmatic therapy achieve clinical remission: Evidence from the Severe Asthma Network in Italy (SANI)
door: Giorgio Walter Canonica, MD, et al.
Gepubliceerd in: (2025-01-01)

Tezepelumab: patient selection and place in therapy in severe asthma
door: Francesco Menzella, et al.
Gepubliceerd in: (2024-04-01)

Treatment strategies for asthma: reshaping the concept of asthma management
door: Alberto Papi, et al.
Gepubliceerd in: (2020-08-01)

Omalizumab as add‐on therapy in a patient with severe asthma and OSA
door: Giulia Scioscia, et al.
Gepubliceerd in: (2020-03-01)

Efficacy of Mepolizumab in patients with previous Omalizumab treatment failure: real life observation
door: Diego Bagnasco, et al.
Gepubliceerd in: (2020-08-01)

The evidence on tiotropium bromide in asthma: from the rationale to the bedside
door: Dejan Radovanovic, et al.
Gepubliceerd in: (2017-05-01)

Real-life effects of dupilumab in patients with severe type 2 asthma, according to atopic trait and presence of chronic rhinosinusitis with nasal polyps
door: Corrado Pelaia, et al.
Gepubliceerd in: (2023-03-01)

Vascular remodeling and TSLP/angiogenin overexpression in severe mixed asthma
door: Francesca Bertolini, et al.
Gepubliceerd in: (2025-02-01)

Erratum to: The evidence on tiotropium bromide in asthma: from the rationale to the bedside
door: Dejan Radovanovic, et al.
Gepubliceerd in: (2017-06-01)

Mabs for treating asthma: omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab
door: Erminia Ridolo, et al.
Gepubliceerd in: (2020-10-01)

Brittle asthma
door: O. Toungoussova, et al.
Gepubliceerd in: (2016-02-01)

Long-term effectiveness of benralizumab in severe eosinophilic asthma patients treated for 96-weeks: data from the ANANKE study
door: Alessandra Vultaggio, et al.
Gepubliceerd in: (2023-05-01)

Expression profiling of miRNA-145 and miRNA-338 in serum and sputum of patients with COPD, asthma, and asthma–COPD overlap syndrome phenotype
door: Lacedonia D, et al.
Gepubliceerd in: (2017-06-01)

Clinical and economic consequences of switching from omalizumab to mepolizumab in uncontrolled severe eosinophilic asthma
door: Giovanna Elisiana Carpagnano, et al.
Gepubliceerd in: (2021-03-01)

SANI-Severe Asthma Network in Italy: a way forward to monitor severe asthma
door: G. Senna, et al.
Gepubliceerd in: (2017-04-01)

Benralizumab in Patients With Severe Eosinophilic Asthma With and Without Chronic Rhinosinusitis With Nasal Polyps: An ANANKE Study post-hoc Analysis
door: Maria D'Amato, et al.
Gepubliceerd in: (2022-05-01)

Predictors of reversible airway obstruction with omalizumab in severe asthma: a real-life study
door: Paolo Solidoro, et al.
Gepubliceerd in: (2019-04-01)

The clinical profile of benralizumab in the management of severe eosinophilic asthma
door: Francesco Menzella, et al.
Gepubliceerd in: (2016-12-01)

Positioning tezepelumab for patients with severe asthma: from evidence to unmet needs
door: Carlo Lombardi, et al.
Gepubliceerd in: (2024-11-01)

The extracellular matrix of the lung and airway responsiveness in asthma
door: F.G. Salerno, et al.
Gepubliceerd in: (2016-01-01)

Alexithymia and asthma: a systematic review
door: Orlando Silvestro, et al.
Gepubliceerd in: (2023-08-01)

Very long-term data on patients with severe eosinophilic asthma treated with mepolizumab: a case series
door: Carlo Lombardi, et al.
Gepubliceerd in: (2024-07-01)

“Characteristics of patients admitted to emergency department for asthma attack: a real-LIFE study”
door: Laura Losappio, et al.
Gepubliceerd in: (2019-06-01)

Interleukin-5 in the Pathophysiology of Severe Asthma
door: Corrado Pelaia, et al.
Gepubliceerd in: (2019-12-01)

Role of Leukotrienes and Leukotriene Modifiers in Asthma
door: Paolo Montuschi
Gepubliceerd in: (2010-06-01)